TGR-1202 (umbralisib)

February 26, 2018February 26, 2018

Umbralisib Shows Promise in Treating Lymphoma, Leukemia in Phase 1 Clinical Trial

News

Umbralisib, being developed by TG Therapeutics, showed positive results in the treatment of chronic lymphocytic leukemia and lymphoma patients in a Phase 1 clinical trial. The study, “Umbralisib, a novel ... Read more

August 16, 2017August 16, 2017

TGR-1202 and TG-1101 Combo Is Effective Enough Against Lymphoma to Continue Being Tested in Phase 2 Trial

News

A combination of two of TG Therapeutics’ lymphoma treatments proved effective enough to continue enrolling patients in a Phase 2b clinical trial, the company announced. But one of the two failed ... Read more

June 22, 2017

At Least Four-fifths of Leukemia and Lymphoma Patients Respond to TRG-1202 Combo Therapy, Researchers Report

News

Ninety-four percent of patients with chronic lymphocytic leukemia and 79 percent with mantle cell lymphoma responded to treatment with a combination of TGR-1202 (umbralisib), Imbruvica (ibrutinib), and TG-1101, according to updated Phase ... Read more